BioSpace News Archive

Tilak Healthcare, a leader in the field of digital health solutions for monitoring chronic ophthalmic diseases, announces positive results from its TIL002 clinical trial aimed at validating the OdySight® mobile app as a tool allowing patients to measure their visual acuity at home by themselves.

Aclarion, Inc. announced that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.

Abpro Corporation and Atlantic Coastal Acquisition Corp. II announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination.

Galderma announced it has received approval from Health Canada for Restylane® SHAYPE™, a hyaluronic acid injectable designed for temporary augmentation of the chin region.2 Engineered to build and shape on bone with deep injection for a bone-mimicking effect,1,2,3,4† Restylane® SHAYPE™ will be available in Canada as of February 2024.

ANGLE plc is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal - “Current Issues in Molecular Biology” Special Issue: Advanced Solutions for Cancer Therapy.

Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.

Abivax SA, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, provides an outlook on its 2024 strategic priorities and milestones.

Bionomics Limited, a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, provided a 2023 review and its outlook for 2024.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 – 27 January 2024.

Oculis Holding AG today announced it will host an in-person R&D Day in Midtown, New York City, on Wednesday, February 28, 2024 from 9:00 AM to 11:00 AM ET.